Silence Therapeutics (SLN) Invested Capital (2018 - 2026)

Silence Therapeutics has disclosed Invested Capital across 9 years of filings, most recently posting $49.4 million for Q1 2026.

• Invested Capital for Q1 2026 came in at $49.4 million, down 56.18% year-over-year; the trailing twelve-month figure through Mar 2026 was $49.4 million (down 56.18% YoY), and the FY2025 annual result was $62.3 million, down 53.51% from the prior year.
• Invested Capital came in at $49.4 million for Q1 2026 at Silence Therapeutics, down from $62.3 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $156.8 million in Q1 2024 to a low of $21.2 million in Q4 2023.
• The 5-year median for Invested Capital is $94.2 million (2025), against an average of $90.9 million.
• Across the five-year window, Invested Capital surged 533.33% in 2024 and sank 56.18% in 2026, its largest moves.
• Silence Therapeutics' Invested Capital stood at $25.9 million in 2022, then dropped by 18.26% to $21.2 million in 2023, then soared by 533.33% to $134.0 million in 2024, then tumbled by 53.51% to $62.3 million in 2025, then slipped by 20.71% to $49.4 million in 2026.
• The last three Invested Capital figures came in at $49.4 million (Q1 2026), $62.3 million (Q4 2025), and $74.1 million (Q3 2025), per Business Quant data.